Overexpression of the Novel Senescence Marker [beta]-Galactosidase (GLB1) in Prostate Cancer Predicts Reduced PSA Recurrence

Senescence is a terminal growth arrest that functions as a tumor suppressor in aging and precancerous cells and is a response to selected anticancer compounds. Lysosomal-[beta]-galactosidase (GLB1) hydrolyzes [beta]-galactose from glycoconjugates and is the origin of senescence-associated [beta]-gal...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-04, Vol.10 (4)
Main Authors: Wagner, Jennifer, Damaschke, Nathan, Yang, Bing, Truong, Matthew, Guenther, Chad, McCormick, Johnathon, Huang, Wei, Jarrard, David
Format: Article
Language:English
Subjects:
Chemotherapy
Formaldehyde
Galactose
Prognosis
Prostate cancer
Recurrence (Disease)
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Senescence is a terminal growth arrest that functions as a tumor suppressor in aging and precancerous cells and is a response to selected anticancer compounds. Lysosomal-[beta]-galactosidase (GLB1) hydrolyzes [beta]-galactose from glycoconjugates and is the origin of senescence-associated [beta]-gal activity (SA-[beta]-gal). Using a new GLB1 antibody, senescence biology was investigated in prostate cancer (PCa) tissues. GLB1 expression accumulates in replicative and induced senescence and correlates with senescent morphology and P16 (CDKN2) expression. In tissue arrays, quantitative imaging detects increased GLB1 expression in high-grade prostatic intraepithelial neoplasia (HGPIN), known to contain senescent cells, and cancer compared to benign prostate tissues (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0124366